Saflon Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 29-06-2024
- Paid Up Capital ₹ 0.10 M
as on 29-06-2024
- Company Age 9 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 27.02%
(FY 2022)
- Profit 15.86%
(FY 2022)
- Ebitda 30.76%
(FY 2022)
- Net Worth 31.42%
(FY 2022)
- Total Assets 3.41%
(FY 2022)
About Saflon Lifesciences
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nihil Patel, Ayushi Patel, and Rakeshkumar Patel serve as directors at the Company.
- CIN/LLPIN
U24100GJ2015PTC084555
- Company No.
084555
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Sep 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Saflon Lifesciences Private Limited offer?
Saflon Lifesciences Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Ayurvedic, Herbal Oils and Cosmetics, Herbal Skin Care Cosmetics, Cosmetics, Hair & Beauty Products, Face Cream, Ayurvedic Herbal Syrups & Tonics, Diabetic Herbal Medicine.
Who are the key members and board of directors at Saflon Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ayushi Patel  | Director | 03-Jan-2020 | Current |
| Nihil Patel | Director | 22-Sep-2015 | Current |
| Rakeshkumar Patel | Additional Director | 20-Jun-2023 | Current |
Financial Performance of Saflon Lifesciences.
Saflon Lifesciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 27.02% increase. The company also saw a substantial improvement in profitability, with a 15.86% increase in profit. The company's net worth Soared by an impressive increase of 31.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Saflon Lifesciences?
In 2021, Saflon Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Saflon Lifesciences?
Unlock and access historical data on people associated with Saflon Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Saflon Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Saflon Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
